Ibrutinib: the home run for cure in CLL?

Wendtner, Clemens-Martin (2019): Ibrutinib: the home run for cure in CLL? In: Blood, Bd. 133, Nr. 19: S. 2003-2004

Abstract

In this issue of Blood, Byrd et al report that after nearly 4 years of follow-up, there is an impressive and sustained progression-free survival and overall survival benefit to using the Bruton's tyrosine kinase inhibitor ibrutinib vs ofatumumab in patients with relapsed or refractory (r/r) chronic lymphocytic leukemia (CLL). Nevertheless, patients with specific high-risk features like TP53 or SF3B1 mutations showed a trend toward shorter progression-free survival, and altogether, only half of the enrolled patients were still receiving ibrutinib at the end of the observation period. 1

• Dokumententyp: Zeitschriftenartikel
• Fakultät: Medizin
• Themengebiete: 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit
• ISSN: 0006-4971
• Sprache: Englisch